Literature DB >> 8340384

Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell.

K Sugino1, N Kurosawa, T Nakamura, K Takio, S Shimasaki, N Ling, K Titani, H Sugino.   

Abstract

Follistatin (FS), an activin-binding protein, is a monomer derived from two polypeptide core sequences of 315 (FS-315) and 288 (FS-288) amino acids originated from alternatively spliced mRNA. To define the structural heterogeneity of native FS, we purified six molecular forms of FS from porcine ovaries. Protein chemical analysis revealed that the structural differences among the six isoforms were caused by truncation of the carboxyl-terminal region and/or the presence of carbohydrate chains, resulting in the formation of FS-315, FS-288, and FS composed of 303 amino acids (FS-303) in various forms of glycosylation on the two potential Asn-linked glycosylation sites. The majority of FS isolated from porcine ovaries was FS-303, which may have been derived from FS-315 by proteolytic cleavage of the 12 COOH-terminal amino acids. All six molecular species have almost the same activin binding activity (Kd = 540-680 pM). By contrast, the COOH-terminal truncated form, FS-288, showed much higher affinity for the rat granulosa cell surface than FS-303, whereas FS-315 had no affinity. FS-288 bound to heparan sulfate-Sepharose CL-4B, but FS-315 did not, suggesting that the truncated forms of FS bind to heparan sulfate proteoglycans on the cell. COS cells transfected with the FS-288 DNA expressed the FS-288 protein, which adhered to the cell surface, but cells transfected with the FS-315 DNA secreted the expressed protein into the medium, which did not bind to the cell surface. In rat anterior pituitary culture, FS-288 (ED50 = 2 ng/ml) was more potent in suppressing follicle-stimulating hormone release than FS-303 (ED50 = 10 ng/ml) and FS-315 (ED50 = 20 ng/ml). These results suggest that cell-associated FS traps activin more tightly in the matrix, thereby more effectively blocking the activity of activin on heparan sulfate proteoglycans of the cell surface and that cell-associated FS plays an important role in controlling the various actions of activin in a paracrine or autocrine manner.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8340384

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  Overexpression of follistatin in the mouse epididymis disrupts fluid resorption and sperm transit in testicular excurrent ducts.

Authors:  Darcie D Seachrist; Emhonta Johnson; Christianne Magee; Colin M Clay; James K Graham; D N Rao Veeramachaneni; Ruth A Keri
Journal:  Biol Reprod       Date:  2012-08-23       Impact factor: 4.285

2.  A targeted proteomic assay for the measurement of plasma proteoforms related to human aging phenotypes.

Authors:  Richard D Semba; Pingbo Zhang; Min Zhu; Elisa Fabbri; Marta Gonzalez-Freire; Ruin Moaddel; Minghui Geng-Spyropoulos; Luigi Ferrucci
Journal:  Proteomics       Date:  2017-08       Impact factor: 3.984

Review 3.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

4.  Identification and characterization of a novel heparan sulfate-binding domain in Activin A longest variants and implications for function.

Authors:  Evan Yang; Christina Mundy; Eric F Rappaport; Maurizio Pacifici; Paul C Billings
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

Review 5.  Agonists and Antagonists of TGF-β Family Ligands.

Authors:  Chenbei Chang
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

Review 6.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

Review 7.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

Review 8.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 9.  The biology of activin: recent advances in structure, regulation and function.

Authors:  Yin Xia; Alan L Schneyer
Journal:  J Endocrinol       Date:  2009-03-09       Impact factor: 4.286

10.  The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.

Authors:  Robin Stamler; Henry T Keutmann; Yisrael Sidis; Chandramohan Kattamuri; Alan Schneyer; Thomas B Thompson
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.